Physician profile
Karan Lal
NPI 1679928832
$643,986.69
in general payments reported to CMS, 2019-2025
38 companies · $256K in 2025
The $256K reported for 2025 was more than what 98% of Pediatric Dermatology providers received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.90 · 2021: $487 · 2022: $26K · 2023: $124K · 2024: $238K · 2025: $256K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $416K · Consulting Fee: $114K · Travel and Lodging: $42K · Food and Beverage: $26K · Honoraria: $10K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,942 · Education: $394 · Gift: $43.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $416,427.33 |
| Consulting Fee | $113,769.80 |
| Travel and Lodging | $42,391.02 |
| Food and Beverage | $26,219.40 |
| Honoraria | $10,451.97 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,942.00 |
| Education | $393.79 |
| Gift | $43.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $184,894.11 | 2022-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $106,216.90 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Genzyme Corporation | $62,438.80 | 2021-2025 | |
| Abbvie INC. | $52,771.05 | 2022-2025 | |
| Lilly USA, LLC | $43,878.75 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $37,442.20 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $27,976.48 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $23,528.81 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Eli Lilly and Company | $22,519.26 | 2024-2025 | Olumiant, Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19,513.61 | 2022-2025 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $17,140.96 | 2021-2025 | Dupixent, Libtayo |
| Organon LLC | $12,396.42 | 2025 | Vtama |
| Botanix Sb INC | $9,574.99 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $7,903.30 | 2024-2025 | Ycanth |
| Amgen INC. | $4,662.21 | 2021-2025 | Otezla, Otezla, Enbrel |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $3,345.62 | 2023-2024 | Vtama |
| Galderma Research & Development, LLC | $2,528.75 | 2023 | |
| Avita Medical Americas, LLC | $1,000.00 | 2024 | |
| Janssen Biotech, INC. | $902.19 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Leo Pharma INC. | $804.17 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $564.77 | 2022-2025 | Sotyktu |
| Journey Medical Corporation | $319.25 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $312.83 | 2022-2025 | |
| Ucb, INC. | $225.82 | 2024-2025 | Bimzelx |
| Paratek Pharmaceuticals, INC. | $174.61 | 2024-2025 | Nuzyra |
| Fidia Pharma USA INC. | $162.38 | 2024-2025 | |
| Epi Health, LLC | $144.16 | 2021-2022 | |
| Biofrontera INC. | $114.87 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $104.03 | 2021-2025 | Jublia |
| Kyowa Kirin, INC. | $91.22 | 2025 | |
| Mayne Pharma Commercial LLC | $80.10 | 2025 | |
| Almirall LLC | $68.91 | 2021-2023 | Klisyri |
| Strata Skin Sciences, INC. | $46.06 | 2025 | Xtrac |
| Krystal Biotech INC | $43.22 | 2023 | Vyjuvek |
| Allergan, INC. | $30.34 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $26.29 | 2024 | Hemangeol |
| Dermira, INC. | $21.90 | 2020 | |
| Celltrion USA INC. | $17.35 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Lal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.